cancer, tumors
CANCER, TUMORS, APC
The Following treatment, cells were characterized for transcriptional changes (NanoString Technologies), activation by cell surface or intracellular flow cytometry, or IFNγ production by Meso Scale Discovery (MSD, Meso Scale Diagnostics, LLC). All analysis of cytokine production (i.e., IFNγ) by MSD was performed on cell-free supernatants. For PBMC from patients with cancer, an overnight rest step was included prior to treatment initiation.A modified MLR [i.e., allogeneic dendritic cell (DC) MLR] was also used to assess the functional activity of feladilimab alone and in combination with anti-PD-1 (pembrolizumab). Immature monocyte-derived antigen-presenting cells (APC) were first generated by exposing plate-adhered human PBMC to recombinant human GMCSF (1,000 U/mL, PeproTech) and IL4 (500 U/mL, PeproTech) in serum-free AIM-V medium (Thermo Fisher Scientific) for 8 days at 37°C and 5% COPrimary tumors from patients were dissociated using a gentleMACS